acs

Megestrol acetate (BDH1298) is a progestogen with actions and uses similar to those of the progestogens in general. Megestrol acetate also has anti-androgenic properties. It is given by mouth in the palliative treatment or as an adjunct to other therapy in endometrial carcinoma and in breast cancer. Megestrol acetate has been approved to treat anorexia and cachexia.

Sodium diethylcarbamodithioate trihydrate, ACS, 99.0% (Ditiocarb sodium trihydrate, ACS, 99.0%), is a copper reagent that reacts with Cu2+ solutions to form complexes, enhancing the rate of copper precipitation. Additionally, it has potential in reducing HIV infection and is employed in adjuvant immune research for high-risk breast cancer.

Sodium oxalate, ACS, 99.5% (Ethanedioic acid (sodium), ACS, 99.5%), is a biochemical reagent.

Potassium chloride, ACS, 99.0% is a metal halide salt composed of potassium and chlorine.

Calcium acetate monohydrate, ACS, 99%, is a calcium acetate monohydrate employed for the precipitation of oxalates in solutions. Additionally, it serves as a stabilizer, buffer, and chelating agent.

IACS-52825 is a selective and potent dual leucine zipper kinase (DLK) inhibitor that reverses para-mechanical aberrant pain in a CIPN mouse model for the study of neurological disorders.

IACS-010759 is an orally bioavailable inhibitor of complex I of oxidative phosphorylation of the mitochondrial electron transport chain.

HDACs mTOR Inhibitor 1 is a dual HDAC and mammalian target of Rapamycin (mTOR) inhibitor for treating hematologic malignancies, with IC50 values of 0.19 nM, 1.8 nM, 1.2 nM, and >500 nM for HDAC1, HDAC6, mTOR, and PI3Kα, respectively.

IACS-8779 is a potent STING agonist that efficiently stimulates interferon gene activity and exhibits strong systemic antitumor effects.

IACS-8803 is a potent cyclic dinucleotide STING agonist that exhibits strong systemic antitumor efficacy.

IACS-9571 is a selective and potent inhibitor of TRIM24 and BRPF1, (IC50: 8 nM for TRIM24; Kds: 31 nM and 14 nM for TRIM24 and BRPF1).

IACS-8968 is a dual IDO and TDO inhibitor (pIC50s: 6.43 for IDO and <5 for TDO).

IACS-8968 R-enantiomer is the R-enantiomer of IACS-8968. IACS-8968 is a dual IDO and TDO inhibitor (pIC50s: 6.43 for IDO and <5 for TDO).

IACS-8968 S-enantiomer is the S-enantiomer of IACS-8968. IACS-8968 is a dual IDO and TDO inhibitor (pIC50s: 6.43 for IDO and <5 for TDO).

Triacsin C (WS 1228A) from Streptomyces aureofaciens is a differential inhibitor of arachidonic acid coenzyme A synthetase and non-specific long-chain acyl-coenzyme A synthetase, with anti-atherosclerotic activity, inhibition of ACSL activity, and inhibition of the accumulation of TAGs into lipid droplets (LDs).Triacsin C has been used to study rotavirus infection and Alzheimer;s disease. Triacsin C is used to study rotavirus infection and Alzheimer;s disease.

HDACs EZH2-IN-1 (Compound 22a) is a dual inhibitor of HDACs and EZH2, exhibiting potent inhibitory activity, with EZH2 Y641N being suppressed by 98% at 50 nM. It selectively targets HDAC1 and HDAC6, with IC50 values of 0.23 μM and 0.07 μM, respectively. HDACs EZH2-IN-1 effectively inhibits the proliferation of diffuse large B-cell lymphoma cells harboring EZH2 mutations and various acute myeloid leukemia cells. Additionally, this compound has the capability to induce cellular differentiation and apoptosis (Apoptosis).

AAK1 HDACs-IN-1 (Compound 12) is a dual inhibitor targeting AAK1 and HDACs, effectively inhibiting AAK1, HDAC1, and HDAC6, with IC50 values of 15.9, 148.6, and 5.2 nM, respectively. This compound also hinders SARS-CoV-2 infection by blocking the endocytosis of the ACE2-SARS-CoV-2 complex and the AP2M1-ACE2 interaction.

ACSF is often used as a replacement of CSF for perfusion of brain slices to preserve interneurons. ACSF is invented to reduce the incidence of cerebral edema and further suppress brain cell disorders. And ACSF is often used as an irrigation fluid or perfu

GW5638 is a estrogen receptor ligand. GW5638 is a prodrug of its active metabolite GW7604. GW5638 appears to act as an antagonist in these in vitro systems, although in a manner distinct from other known ER modulators. GW5638 is also classified as a pseud

IACS-010759 hydrochloride is an orally potent and selective OXPHOS inhibitor that inhibits proliferation and induces apoptosis in OXPHOS-dependent brain cancer and acute myeloid leukaemia models for the study of relapsed refractory AML and advanced solid tumours.

IACS-15414 is a potent SHP2 inhibitor that is effective when administered orally, demonstrating an IC50 value of 122 nM.

ACSS2-IN-2 (MTB-9655) is an inhibitor of acyl-CoA synthetase short-chain family member 2 (ACSS2). ACSS2-IN-2 can inhibit ACSS2 activity with an IC50 value of 3.8 nM. ACSS2-IN-2 can be used for the research of several diseases, such as viral infection, metabolic disorders, neuropsychiatric diseases, inflammatory autoimmune conditions and cancer.

PHD2 HDACs-IN-1 is a potent mixed inhibitor of PHD2 HDACs, acting on PHD2 (IC50: 1.15 μM), HDAC1 (IC50: 19.75 μM), HDAC2 (IC50: 26.60 μM), and HDAC16 (IC50: 15.98 μM). HDACs-IN-1 is a low toxicity nephroprotective agent suitable for studies of cisplatin-induced acute kidney injury (AKI).

ACSS2-IN-1 is a potent ACSS2 inhibitor with IC50 values ranging from 0.01 nM to <1 nM, suitable for cancer research.